Cancer Biomarkers Market – Scope of Report

TMR’s report on the global Cancer Biomarkers Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Cancer Biomarkers Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Cancer Biomarkers Market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Global Cancer Biomarkers Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the Global Cancer Biomarkers Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the Global Cancer Biomarkers Market. These serve as valuable tools for existing Market players as well as for entities interested in participating in the Global Cancer Biomarkers Market .

The report delves into the competitive landscape of the Global Cancer Biomarkers Market. Key players operating in the global Cancer Biomarkers Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Cancer Biomarkers Market profiled in this report.

Key Questions Answered in Global Cancer Biomarkers Market Report

• What is the sales/revenue generated by Cancer Biomarkers Market across all regions during the forecast period?
• What are the opportunities in the global Cancer Biomarkers Market?
• What are the major drivers, restraints, opportunities, and threats in the Market?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market?

Global Cancer Biomarkers Market – Research Objectives and Research Approach

The comprehensive report on the global Cancer Biomarkers Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Cancer Biomarkers Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market Share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the Cancer Biomarkers Market.

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biomarkers Market Analysis and Forecast, 2021-2036
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Healthcare Expenditure by Country/Region
5.2. Recent Technological Advancements
5.3. Regulatory Scenario across Key Countries / Regions
5.4. PORTER’s Five Forces Analysis
5.5. Consumer Behavior & End-User Insights
5.6. PESTLE Analysis
5.7. Key Industry Events
5.8. Distributors Landscape
5.9. Go to Marketing Strategies for New Entrants
5.10. Pricing Analysis
6. Global Cancer Biomarkers Market Analysis and Forecast, by Biomarker Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Biomarker Type, 2021-2036
6.3.1. Genetic Biomarker
6.3.1.1. BRAF
6.3.1.2. ALK
6.3.1.3. Others
6.3.2. Protein Biomarker
6.3.2.1. CA-125
6.3.2.2. HER2
6.3.2.3. Prostate-specific antigen (PSA)
6.3.2.4. Alfa-fetoprotein
6.3.2.5. Human chorionic gonadotropin-β
6.3.2.6. Calcitonin
6.3.2.7. CA 15-3
6.3.2.8. Others
6.3.3. Cells as Cancer Biomarkers
6.3.3.1. Circulating Tumor Cells
6.3.3.2. Immune Cells
6.3.3.3. Others
6.3.4. Others
6.4. Market Attractiveness Analysis, by Biomarker Type
7. Global Cancer Biomarkers Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2021-2036
7.3.1. Breast Cancer
7.3.2. Prostate Cancer
7.3.3. Ovarian Cancer
7.3.4. Colorectal Cancer
7.3.5. Thyroid Cancer
7.3.6. Testicular Cancer
7.3.7. Liver Cancer
7.3.8. Kidney Cancer
7.3.9. Colon Cancer
7.3.10. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Cancer Biomarkers Market Analysis and Forecast, by Profiling Technologies
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Profiling Technologies, 2021-2036
8.3.1. Omics Technologies
8.3.1.1. Proteomics
8.3.1.2. Genomics
8.3.1.3. Others
8.3.2. Imaging Technologies
8.3.2.1. Ultrasound Imaging
8.3.2.2. Positron Emission Tomography
8.3.2.3. Magnetic Resonance Imaging
8.3.2.4. Others
8.3.3. Others
8.4. Market Attractiveness Analysis, by Profiling Technologies
9. Global Cancer Biomarkers Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2021-2036
9.3.1. Diagnostic Laboratories
9.3.2. Biopharmaceutical Companies
9.3.3. Hospitals & Specialty Clinics
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Cancer Biomarkers Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2021-2036
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Cancer Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Biomarker Type, 2021-2036
11.2.1. Genetic Biomarker
11.2.1.1. BRAF
11.2.1.2. ALK
11.2.1.3. Others
11.2.2. Protein Biomarker
11.2.2.1. CA-125
11.2.2.2. HER2
11.2.2.3. Prostate-specific antigen (PSA)
11.2.2.4. Alfa-fetoprotein
11.2.2.5. Human chorionic gonadotropin-β
11.2.2.6. Calcitonin
11.2.2.7. CA 15-3
11.2.2.8. Others
11.2.3. Cells as Cancer Biomarkers
11.2.3.1. Circulating Tumor Cells
11.2.3.2. Immune Cells
11.2.3.3. Others
11.2.4. Others
11.3. Market Value Forecast, by Cancer Type, 2021-2036
11.3.1. Breast Cancer
11.3.2. Prostate Cancer
11.3.3. Ovarian Cancer
11.3.4. Colorectal Cancer
11.3.5. Thyroid Cancer
11.3.6. Testicular Cancer
11.3.7. Liver Cancer
11.3.8. Kidney Cancer
11.3.9. Colon Cancer
11.3.10. Others
11.4. Market Value Forecast, by Profiling Technologies, 2021-2036
11.4.1. Omics Technologies
11.4.1.1. Proteomics
11.4.1.2. Genomics
11.4.1.3. Others
11.4.2. Imaging Technologies
11.4.2.1. Ultrasound Imaging
11.4.2.2. Positron Emission Tomography
11.4.2.3. Magnetic Resonance Imaging
11.4.2.4. Others
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2021-2036
11.5.1. Diagnostic Laboratories
11.5.2. Biopharmaceutical Companies
11.5.3. Hospitals & Specialty Clinics
11.5.4. Others
11.6. Market Value Forecast, by Country, 2021-2036
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Biomarker Type
11.7.2. By Cancer Type
11.7.3. By Profiling Technologies
11.7.4. By End-user
11.7.5. By Country
12. U.S. Cancer Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Biomarker Type, 2021-2036
12.2.1. Genetic Biomarker
12.2.1.1. BRAF
12.2.1.2. ALK
12.2.1.3. Others
12.2.2. Protein Biomarker
12.2.2.1. CA-125
12.2.2.2. HER2
12.2.2.3. Prostate-specific antigen (PSA)
12.2.2.4. Alfa-fetoprotein
12.2.2.5. Human chorionic gonadotropin-β
12.2.2.6. Calcitonin
12.2.2.7. CA 15-3
12.2.2.8. Others
12.2.3. Cells as Cancer Biomarkers
12.2.3.1. Circulating Tumor Cells
12.2.3.2. Immune Cells
12.2.3.3. Others
12.2.4. Others
12.3. Market Value Forecast, by Cancer Type, 2021-2036
12.3.1. Breast Cancer
12.3.2. Prostate Cancer
12.3.3. Ovarian Cancer
12.3.4. Colorectal Cancer
12.3.5. Thyroid Cancer
12.3.6. Testicular Cancer
12.3.7. Liver Cancer
12.3.8. Kidney Cancer
12.3.9. Colon Cancer
12.3.10. Others
12.4. Market Value Forecast, by Profiling Technologies, 2021-2036
12.4.1. Omics Technologies
12.4.1.1. Proteomics
12.4.1.2. Genomics
12.4.1.3. Others
12.4.2. Imaging Technologies
12.4.2.1. Ultrasound Imaging
12.4.2.2. Positron Emission Tomography
12.4.2.3. Magnetic Resonance Imaging
12.4.2.4. Others
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2021-2036
12.5.1. Diagnostic Laboratories
12.5.2. Biopharmaceutical Companies
12.5.3. Hospitals & Specialty Clinics
12.5.4. Others
12.6. Market Attractiveness Analysis
12.6.1. By Biomarker Type
12.6.2. By Cancer Type
12.6.3. By Profiling Technologies
12.6.4. By End-user
13. Canada Cancer Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Biomarker Type, 2021-2036
13.2.1. Genetic Biomarker
13.2.1.1. BRAF
13.2.1.2. ALK
13.2.1.3. Others
13.2.2. Protein Biomarker
13.2.2.1. CA-125
13.2.2.2. HER2
13.2.2.3. Prostate-specific antigen (PSA)
13.2.2.4. Alfa-fetoprotein
13.2.2.5. Human chorionic gonadotropin-β
13.2.2.6. Calcitonin
13.2.2.7. CA 15-3
13.2.2.8. Others
13.2.3. Cells as Cancer Biomarkers
13.2.3.1. Circulating Tumor Cells
13.2.3.2. Immune Cells
13.2.3.3. Others
13.2.4. Others
13.3. Market Value Forecast, by Cancer Type, 2021-2036
13.3.1. Breast Cancer
13.3.2. Prostate Cancer
13.3.3. Ovarian Cancer
13.3.4. Colorectal Cancer
13.3.5. Thyroid Cancer
13.3.6. Testicular Cancer
13.3.7. Liver Cancer
13.3.8. Kidney Cancer
13.3.9. Colon Cancer
13.3.10. Others
13.4. Market Value Forecast, by Profiling Technologies, 2021-2036
13.4.1. Omics Technologies
13.4.1.1. Proteomics
13.4.1.2. Genomics
13.4.1.3. Others
13.4.2. Imaging Technologies
13.4.2.1. Ultrasound Imaging
13.4.2.2. Positron Emission Tomography
13.4.2.3. Magnetic Resonance Imaging
13.4.2.4. Others
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2021-2036
13.5.1. Diagnostic Laboratories
13.5.2. Biopharmaceutical Companies
13.5.3. Hospitals & Specialty Clinics
13.5.4. Others
13.6. Market Attractiveness Analysis
13.6.1. By Biomarker Type
13.6.2. By Cancer Type
13.6.3. By Profiling Technologies
13.6.4. By End-user
14. Europe Cancer Biomarkers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Biomarker Type, 2021-2036
14.2.1. Genetic Biomarker
14.2.1.1. BRAF
14.2.1.2. ALK
14.2.1.3. Others
14.2.2. Protein Biomarker
14.2.2.1. CA-125
14.2.2.2. HER2
14.2.2.3. Prostate-specific antigen (PSA)
14.2.2.4. Alfa-fetoprotein
14.2.2.5. Human chorionic gonadotropin-β
14.2.2.6. Calcitonin
14.2.2.7. CA 15-3
14.2.2.8. Others
14.2.3. Cells as Cancer Biomarkers
14.2.3.1. Circulating Tumor Cells
14.2.3.2. Immune Cells
14.2.3.3. Others
14.2.4. Others
14.3. Market Value Forecast, by Cancer Type, 2021-2036
14.3.1. Breast Cancer
14.3.2. Prostate Cancer
14.3.3. Ovarian Cancer
14.3.4. Colorectal Cancer
14.3.5. Thyroid Cancer
14.3.6. Testicular Cancer
14.3.7. Liver Cancer
14.3.8. Kidney Cancer
14.3.9. Colon Cancer
14.3.10. Others
14.4. Market Value Forecast, by Profiling Technologies, 2021-2036
14.4.1. Omics Technologies
14.4.1.1. Proteomics
14.4.1.2. Genomics
14.4.1.3. Others
14.4.2. Imaging Technologies
14.4.2.1. Ultrasound Imaging
14.4.2.2. Positron Emission Tomography
14.4.2.3. Magnetic Resonance Imaging
14.4.2.4. Others
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2021-2036
14.5.1. Diagnostic Laboratories
14.5.2. Biopharmaceutical Companies
14.5.3. Hospitals & Specialty Clinics
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2021-2036
14.6.1. Germany
14.6.2. U.K.
14.6.3. France
14.6.4. Italy
14.6.5. Spain
14.6.6. The Netherlands
14.6.7. Rest of Europe
14.7. Market Attractiveness Analysis
14.7.1. By Biomarker Type
14.7.2. By Cancer Type
14.7.3. By Profiling Technologies
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Germany Cancer Biomarkers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Biomarker Type, 2021-2036
15.2.1. Genetic Biomarker
15.2.1.1. BRAF
15.2.1.2. ALK
15.2.1.3. Others
15.2.2. Protein Biomarker
15.2.2.1. CA-125
15.2.2.2. HER2
15.2.2.3. Prostate-specific antigen (PSA)
15.2.2.4. Alfa-fetoprotein
15.2.2.5. Human chorionic gonadotropin-β
15.2.2.6. Calcitonin
15.2.2.7. CA 15-3
15.2.2.8. Others
15.2.3. Cells as Cancer Biomarkers
15.2.3.1. Circulating Tumor Cells
15.2.3.2. Immune Cells
15.2.3.3. Others
15.2.4. Others
15.3. Market Value Forecast, by Cancer Type, 2021-2036
15.3.1. Breast Cancer
15.3.2. Prostate Cancer
15.3.3. Ovarian Cancer
15.3.4. Colorectal Cancer
15.3.5. Thyroid Cancer
15.3.6. Testicular Cancer
15.3.7. Liver Cancer
15.3.8. Kidney Cancer
15.3.9. Colon Cancer
15.3.10. Others
15.4. Market Value Forecast, by Profiling Technologies, 2021-2036
15.4.1. Omics Technologies
15.4.1.1. Proteomics
15.4.1.2. Genomics
15.4.1.3. Others
15.4.2. Imaging Technologies
15.4.2.1. Ultrasound Imaging
15.4.2.2. Positron Emission Tomography
15.4.2.3. Magnetic Resonance Imaging
15.4.2.4. Others
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2021-2036
15.5.1. Diagnostic Laboratories
15.5.2. Biopharmaceutical Companies
15.5.3. Hospitals & Specialty Clinics
15.5.4. Others
15.6. Market Attractiveness Analysis
15.6.1. By Biomarker Type
15.6.2. By Cancer Type
15.6.3. By Profiling Technologies
15.6.4. By End-user
16. U.K. Cancer Biomarkers Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Biomarker Type, 2021-2036
16.2.1. Genetic Biomarker
16.2.1.1. BRAF
16.2.1.2. ALK
16.2.1.3. Others
16.2.2. Protein Biomarker
16.2.2.1. CA-125
16.2.2.2. HER2
16.2.2.3. Prostate-specific antigen (PSA)
16.2.2.4. Alfa-fetoprotein
16.2.2.5. Human chorionic gonadotropin-β
16.2.2.6. Calcitonin
16.2.2.7. CA 15-3
16.2.2.8. Others
16.2.3. Cells as Cancer Biomarkers
16.2.3.1. Circulating Tumor Cells
16.2.3.2. Immune Cells
16.2.3.3. Others
16.2.4. Others
16.3. Market Value Forecast, by Cancer Type, 2021-2036
16.3.1. Breast Cancer
16.3.2. Prostate Cancer
16.3.3. Ovarian Cancer
16.3.4. Colorectal Cancer
16.3.5. Thyroid Cancer
16.3.6. Testicular Cancer
16.3.7. Liver Cancer
16.3.8. Kidney Cancer
16.3.9. Colon Cancer
16.3.10. Others
16.4. Market Value Forecast, by Profiling Technologies, 2021-2036
16.4.1. Omics Technologies
16.4.1.1. Proteomics
16.4.1.2. Genomics
16.4.1.3. Others
16.4.2. Imaging Technologies
16.4.2.1. Ultrasound Imaging
16.4.2.2. Positron Emission Tomography
16.4.2.3. Magnetic Resonance Imaging
16.4.2.4. Others
16.4.3. Others
16.5. Market Value Forecast, by End-user, 2021-2036
16.5.1. Diagnostic Laboratories
16.5.2. Biopharmaceutical Companies
16.5.3. Hospitals & Specialty Clinics
16.5.4. Others
16.6. Market Attractiveness Analysis
16.6.1. By Biomarker Type
16.6.2. By Cancer Type
16.6.3. By Profiling Technologies
16.6.4. By End-user
17. France Cancer Biomarkers Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Biomarker Type, 2021-2036
17.2.1. Genetic Biomarker
17.2.1.1. BRAF
17.2.1.2. ALK
17.2.1.3. Others
17.2.2. Protein Biomarker
17.2.2.1. CA-125
17.2.2.2. HER2
17.2.2.3. Prostate-specific antigen (PSA)
17.2.2.4. Alfa-fetoprotein
17.2.2.5. Human chorionic gonadotropin-β
17.2.2.6. Calcitonin
17.2.2.7. CA 15-3
17.2.2.8. Others
17.2.3. Cells as Cancer Biomarkers
17.2.3.1. Circulating Tumor Cells
17.2.3.2. Immune Cells
17.2.3.3. Others
17.2.4. Others
17.3. Market Value Forecast, by Cancer Type, 2021-2036
17.3.1. Breast Cancer
17.3.2. Prostate Cancer
17.3.3. Ovarian Cancer
17.3.4. Colorectal Cancer
17.3.5. Thyroid Cancer
17.3.6. Testicular Cancer
17.3.7. Liver Cancer
17.3.8. Kidney Cancer
17.3.9. Colon Cancer
17.3.10. Others
17.4. Market Value Forecast, by Profiling Technologies, 2021-2036
17.4.1. Omics Technologies
17.4.1.1. Proteomics
17.4.1.2. Genomics
17.4.1.3. Others
17.4.2. Imaging Technologies
17.4.2.1. Ultrasound Imaging
17.4.2.2. Positron Emission Tomography
17.4.2.3. Magnetic Resonance Imaging
17.4.2.4. Others
17.4.3. Others
17.5. Market Value Forecast, by End-user, 2021-2036
17.5.1. Diagnostic Laboratories
17.5.2. Biopharmaceutical Companies
17.5.3. Hospitals & Specialty Clinics
17.5.4. Others
17.6. Market Attractiveness Analysis
17.6.1. By Biomarker Type
17.6.2. By Cancer Type
17.6.3. By Profiling Technologies
17.6.4. By End-user
18. Italy Cancer Biomarkers Market Analysis and Forecast
18.1. Introduction
18.1.1. Key Findings
18.2. Market Value Forecast, by Biomarker Type, 2021-2036
18.2.1. Genetic Biomarker
18.2.1.1. BRAF
18.2.1.2. ALK
18.2.1.3. Others
18.2.2. Protein Biomarker
18.2.2.1. CA-125
18.2.2.2. HER2
18.2.2.3. Prostate-specific antigen (PSA)
18.2.2.4. Alfa-fetoprotein
18.2.2.5. Human chorionic gonadotropin-β
18.2.2.6. Calcitonin
18.2.2.7. CA 15-3
18.2.2.8. Others
18.2.3. Cells as Cancer Biomarkers
18.2.3.1. Circulating Tumor Cells
18.2.3.2. Immune Cells
18.2.3.3. Others
18.2.4. Others
18.3. Market Value Forecast, by Cancer Type, 2021-2036
18.3.1. Breast Cancer
18.3.2. Prostate Cancer
18.3.3. Ovarian Cancer
18.3.4. Colorectal Cancer
18.3.5. Thyroid Cancer
18.3.6. Testicular Cancer
18.3.7. Liver Cancer
18.3.8. Kidney Cancer
18.3.9. Colon Cancer
18.3.10. Others
18.4. Market Value Forecast, by Profiling Technologies, 2021-2036
18.4.1. Omics Technologies
18.4.1.1. Proteomics
18.4.1.2. Genomics
18.4.1.3. Others
18.4.2. Imaging Technologies
18.4.2.1. Ultrasound Imaging
18.4.2.2. Positron Emission Tomography
18.4.2.3. Magnetic Resonance Imaging
18.4.2.4. Others
18.4.3. Others
18.5. Market Value Forecast, by End-user, 2021-2036
18.5.1. Diagnostic Laboratories
18.5.2. Biopharmaceutical Companies
18.5.3. Hospitals & Specialty Clinics
18.5.4. Others
18.6. Market Attractiveness Analysis
18.6.1. By Biomarker Type
18.6.2. By Cancer Type
18.6.3. By Profiling Technologies
18.6.4. By End-user
19. Spain Cancer Biomarkers Market Analysis and Forecast
19.1. Introduction
19.1.1. Key Findings
19.2. Market Value Forecast, by Biomarker Type, 2021-2036
19.2.1. Genetic Biomarker
19.2.1.1. BRAF
19.2.1.2. ALK
19.2.1.3. Others
19.2.2. Protein Biomarker
19.2.2.1. CA-125
19.2.2.2. HER2
19.2.2.3. Prostate-specific antigen (PSA)
19.2.2.4. Alfa-fetoprotein
19.2.2.5. Human chorionic gonadotropin-β
19.2.2.6. Calcitonin
19.2.2.7. CA 15-3
19.2.2.8. Others
19.2.3. Cells as Cancer Biomarkers
19.2.3.1. Circulating Tumor Cells
19.2.3.2. Immune Cells
19.2.3.3. Others
19.2.4. Others
19.3. Market Value Forecast, by Cancer Type, 2021-2036
19.3.1. Breast Cancer
19.3.2. Prostate Cancer
19.3.3. Ovarian Cancer
19.3.4. Colorectal Cancer
19.3.5. Thyroid Cancer
19.3.6. Testicular Cancer
19.3.7. Liver Cancer
19.3.8. Kidney Cancer
19.3.9. Colon Cancer
19.3.10. Others
19.4. Market Value Forecast, by Profiling Technologies, 2021-2036
19.4.1. Omics Technologies
19.4.1.1. Proteomics
19.4.1.2. Genomics
19.4.1.3. Others
19.4.2. Imaging Technologies
19.4.2.1. Ultrasound Imaging
19.4.2.2. Positron Emission Tomography
19.4.2.3. Magnetic Resonance Imaging
19.4.2.4. Others
19.4.3. Others
19.5. Market Value Forecast, by End-user, 2021-2036
19.5.1. Diagnostic Laboratories
19.5.2. Biopharmaceutical Companies
19.5.3. Hospitals & Specialty Clinics
19.5.4. Others
19.6. Market Attractiveness Analysis
19.6.1. By Biomarker Type
19.6.2. By Cancer Type
19.6.3. By Profiling Technologies
19.6.4. By End-user
20. The Netherlands Cancer Biomarkers Market Analysis and Forecast
20.1. Introduction
20.1.1. Key Findings
20.2. Market Value Forecast, by Biomarker Type, 2021-2036
20.2.1. Genetic Biomarker
20.2.1.1. BRAF
20.2.1.2. ALK
20.2.1.3. Others
20.2.2. Protein Biomarker
20.2.2.1. CA-125
20.2.2.2. HER2
20.2.2.3. Prostate-specific antigen (PSA)
20.2.2.4. Alfa-fetoprotein
20.2.2.5. Human chorionic gonadotropin-β
20.2.2.6. Calcitonin
20.2.2.7. CA 15-3
20.2.2.8. Others
20.2.3. Cells as Cancer Biomarkers
20.2.3.1. Circulating Tumor Cells
20.2.3.2. Immune Cells
20.2.3.3. Others
20.2.4. Others
20.3. Market Value Forecast, by Cancer Type, 2021-2036
20.3.1. Breast Cancer
20.3.2. Prostate Cancer
20.3.3. Ovarian Cancer
20.3.4. Colorectal Cancer
20.3.5. Thyroid Cancer
20.3.6. Testicular Cancer
20.3.7. Liver Cancer
20.3.8. Kidney Cancer
20.3.9. Colon Cancer
20.3.10. Others
20.4. Market Value Forecast, by Profiling Technologies, 2021-2036
20.4.1. Omics Technologies
20.4.1.1. Proteomics
20.4.1.2. Genomics
20.4.1.3. Others
20.4.2. Imaging Technologies
20.4.2.1. Ultrasound Imaging
20.4.2.2. Positron Emission Tomography
20.4.2.3. Magnetic Resonance Imaging
20.4.2.4. Others
20.4.3. Others
20.5. Market Value Forecast, by End-user, 2021-2036
20.5.1. Diagnostic Laboratories
20.5.2. Biopharmaceutical Companies
20.5.3. Hospitals & Specialty Clinics
20.5.4. Others
20.6. Market Attractiveness Analysis
20.6.1. By Biomarker Type
20.6.2. By Cancer Type
20.6.3. By Profiling Technologies
20.6.4. By End-user
21. Rest of Europe Cancer Biomarkers Market Analysis and Forecast
21.1. Introduction
21.1.1. Key Findings
21.2. Market Value Forecast, by Biomarker Type, 2021-2036
21.2.1. Genetic Biomarker
21.2.1.1. BRAF
21.2.1.2. ALK
21.2.1.3. Others
21.2.2. Protein Biomarker
21.2.2.1. CA-125
21.2.2.2. HER2
21.2.2.3. Prostate-specific antigen (PSA)
21.2.2.4. Alfa-fetoprotein
21.2.2.5. Human chorionic gonadotropin-β
21.2.2.6. Calcitonin
21.2.2.7. CA 15-3
21.2.2.8. Others
21.2.3. Cells as Cancer Biomarkers
21.2.3.1. Circulating Tumor Cells
21.2.3.2. Immune Cells
21.2.3.3. Others
21.2.4. Others
21.3. Market Value Forecast, by Cancer Type, 2021-2036
21.3.1. Breast Cancer
21.3.2. Prostate Cancer
21.3.3. Ovarian Cancer
21.3.4. Colorectal Cancer
21.3.5. Thyroid Cancer
21.3.6. Testicular Cancer
21.3.7. Liver Cancer
21.3.8. Kidney Cancer
21.3.9. Colon Cancer
21.3.10. Others
21.4. Market Value Forecast, by Profiling Technologies, 2021-2036
21.4.1. Omics Technologies
21.4.1.1. Proteomics
21.4.1.2. Genomics
21.4.1.3. Others
21.4.2. Imaging Technologies
21.4.2.1. Ultrasound Imaging
21.4.2.2. Positron Emission Tomography
21.4.2.3. Magnetic Resonance Imaging
21.4.2.4. Others
21.4.3. Others
21.5. Market Value Forecast, by End-user, 2021-2036
21.5.1. Diagnostic Laboratories
21.5.2. Biopharmaceutical Companies
21.5.3. Hospitals & Specialty Clinics
21.5.4. Others
21.6. Market Attractiveness Analysis
21.6.1. By Biomarker Type
21.6.2. By Cancer Type
21.6.3. By Profiling Technologies
21.6.4. By End-user
22. Asia Pacific Cancer Biomarkers Market Analysis and Forecast
22.1. Introduction
22.1.1. Key Findings
22.2. Market Value Forecast, by Biomarker Type, 2021-2036
22.2.1. Genetic Biomarker
22.2.1.1. BRAF
22.2.1.2. ALK
22.2.1.3. Others
22.2.2. Protein Biomarker
22.2.2.1. CA-125
22.2.2.2. HER2
22.2.2.3. Prostate-specific antigen (PSA)
22.2.2.4. Alfa-fetoprotein
22.2.2.5. Human chorionic gonadotropin-β
22.2.2.6. Calcitonin
22.2.2.7. CA 15-3
22.2.2.8. Others
22.2.3. Cells as Cancer Biomarkers
22.2.3.1. Circulating Tumor Cells
22.2.3.2. Immune Cells
22.2.3.3. Others
22.2.4. Others
22.3. Market Value Forecast, by Cancer Type, 2021-2036
22.3.1. Breast Cancer
22.3.2. Prostate Cancer
22.3.3. Ovarian Cancer
22.3.4. Colorectal Cancer
22.3.5. Thyroid Cancer
22.3.6. Testicular Cancer
22.3.7. Liver Cancer
22.3.8. Kidney Cancer
22.3.9. Colon Cancer
22.3.10. Others
22.4. Market Value Forecast, by Profiling Technologies, 2021-2036
22.4.1. Omics Technologies
22.4.1.1. Proteomics
22.4.1.2. Genomics
22.4.1.3. Others
22.4.2. Imaging Technologies
22.4.2.1. Ultrasound Imaging
22.4.2.2. Positron Emission Tomography
22.4.2.3. Magnetic Resonance Imaging
22.4.2.4. Others
22.4.3. Others
22.5. Market Value Forecast, by End-user, 2021-2036
22.5.1. Diagnostic Laboratories
22.5.2. Biopharmaceutical Companies
22.5.3. Hospitals & Specialty Clinics
22.5.4. Others
22.6. Market Value Forecast, by Country/Sub-region, 2021-2036
22.6.1. China
22.6.2. India
22.6.3. Japan
22.6.4. South Korea
22.6.5. Australia
22.6.6. ASEAN
22.6.7. Rest of Asia Pacific
22.7. Market Attractiveness Analysis
22.7.1. By Biomarker Type
22.7.2. By Cancer Type
22.7.3. By Profiling Technologies
22.7.4. By End-user
22.7.5. By Country/Sub-region
23. China Cancer Biomarkers Market Analysis and Forecast
23.1. Introduction
23.1.1. Key Findings
23.2. Market Value Forecast, by Biomarker Type, 2021-2036
23.2.1. Genetic Biomarker
23.2.1.1. BRAF
23.2.1.2. ALK
23.2.1.3. Others
23.2.2. Protein Biomarker
23.2.2.1. CA-125
23.2.2.2. HER2
23.2.2.3. Prostate-specific antigen (PSA)
23.2.2.4. Alfa-fetoprotein
23.2.2.5. Human chorionic gonadotropin-β
23.2.2.6. Calcitonin
23.2.2.7. CA 15-3
23.2.2.8. Others
23.2.3. Cells as Cancer Biomarkers
23.2.3.1. Circulating Tumor Cells
23.2.3.2. Immune Cells
23.2.3.3. Others
23.2.4. Others
23.3. Market Value Forecast, by Cancer Type, 2021-2036
23.3.1. Breast Cancer
23.3.2. Prostate Cancer
23.3.3. Ovarian Cancer
23.3.4. Colorectal Cancer
23.3.5. Thyroid Cancer
23.3.6. Testicular Cancer
23.3.7. Liver Cancer
23.3.8. Kidney Cancer
23.3.9. Colon Cancer
23.3.10. Others
23.4. Market Value Forecast, by Profiling Technologies, 2021-2036
23.4.1. Omics Technologies
23.4.1.1. Proteomics
23.4.1.2. Genomics
23.4.1.3. Others
23.4.2. Imaging Technologies
23.4.2.1. Ultrasound Imaging
23.4.2.2. Positron Emission Tomography
23.4.2.3. Magnetic Resonance Imaging
23.4.2.4. Others
23.4.3. Others
23.5. Market Value Forecast, by End-user, 2021-2036
23.5.1. Diagnostic Laboratories
23.5.2. Biopharmaceutical Companies
23.5.3. Hospitals & Specialty Clinics
23.5.4. Others
23.6. Market Attractiveness Analysis
23.6.1. By Biomarker Type
23.6.2. By Cancer Type
23.6.3. By Profiling Technologies
23.6.4. By End-user